SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Roger Cranwill who wrote (1079)6/27/1997 11:34:00 PM
From: Pseudo Biologist   of 1762
 
Roger, the outcome would be whether people receiving drug will do better re. RA vs, those with placebo. At the same time and thru the trial you have to monitor the "vital" signs of *all* the patients in the trial. In particular, and due to concerns known to some in the scientific community (as told by Bennett here), it makes sense to monitor patients' CD4 counts. This is done for *all* patients as the researchers are not suposed to know who is getting drug and who is getting placebo.

Don brings up the unlikely, but not impossible, scenario in which (some) placebo-receiving patients are the ones showing low CD4+ cell counts. That is we do not know with 100% certainty that the CD4-low patients are the ones getting drug. At least, that's the way I tried to interpret Don's note.

My 2 pennies,

PB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News